Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T23897 |
CLK1/2-IN-3
CLK1/2 inhibitor 3,CLK1/2-inhibitor-3,CLK1/2 IN 3,CLK1/2IN3 |
CDK | Cell Cycle/Checkpoint |
CLK1/2-IN-3(Cpd-3) 是一种具有高效性和选择性的 CLK1 和 CLK2 抑制剂,抗增殖活性,抑制 CLK1、CLK2、SRPK1、SRPK2、SRPK3 的 的活性。CLK1/2-IN-3 可诱导核斑点扩大,可诱导S6K pre-mRNA选择性剪接和随后抑制多种癌细胞类型细胞生长。 | |||
T10836 |
CLK1-IN-1
|
CDK | Cell Cycle/Checkpoint |
CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM). | |||
T23896 |
CLK1/2-IN-1
CLK1/2 inhibitor 1,CLK1/2IN1,CLK1/2-inhibitor-1 |
||
CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2. | |||
T36684 | Ipivivint | ||
Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer[1]. Ipivivint (SW480 cells; 0.01~10 μM; 1 hour) potently inhibits SRSF5/6 phosphorylation[1].Ip... | |||
T36689 | KuWal151 | ||
Potent and selective CLK inhibitor (IC50 values are 28, 88 and 510 nM for CLK4, 1 and 2, respectively). Exhibits no significant activity at CLK3, DYRK, CDK or GSK3 at a concentration of 10 μM. Inhibits growth of a range of cancer cell lines in vitro at subnanomolar concentrations. Walter et al (2018) Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. PLoS One 13 e0196761 PMID:29723265 |